Cited by 640Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement DisordersNuclear Receptors and Signaling

The DOI matches its Crossref record; 238 of the 240 references it cites were found in a registry or an index.

Epidemiology of parkinson’s disease

Open access

Tanner, Caroline M., Goldman, Samuel M.·1996·Neurologic Clinics

DOI 10.1016/s0733-8619(05)70259-0PMC PMC7173037

Open this paper in CoChat — free account

Abstract

The epidemiologic studies reviewed here have provided insights into the etiology of PD. Evidence increasingly suggests that, like many other chronic age-related diseases, PD is a multifactorial disorder, with both genes and environment contributing to risk. As the elderly population of the world grows, incidence and prevalence of PD will continue to increase, underscoring the importance of further delineating risk factors. The introduction of levodopa and other pharmacologic therapies over the last 2 decades has postponed disease morbidity and mortality, but morbidity and mortality still are increased markedly relative to unaffected individuals. The development of therapies that may slow disease progression makes early identification and treatment of PD particularly important. Investigations of early markers of PD, or markers of disease susceptibility, are critical areas for future research. These efforts all will be aided by careful collaboration between epidemiologists and laboratory scientists.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0733-8619(05)70259-0

Cites

238 of 238 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
An Essay on the Shaking Palsy
Parkinson, J. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.2.223 · Cited by 2,856
Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. A., & SEITELBERGER, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,650
Case-Control Studies: Design, Conduct, Analysis.
Youkeles, L., & Schlesselman, J. J. (1983) · Journal of the American Statistical Association · doi:10.2307/2288156 · Cited by 2,358
Vitamin E Consumption and the Risk of Coronary Heart Disease in Men
Rimm, E. B., Stampfer, M. J., Ascherio, A., Giovannucci, E. L., Colditz, G. A., & Willett, W. C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305203282004 · Cited by 2,345
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
Oxygen radicals and human disease
CROSS, C. E., HALLIWELL, B., BORISH, E. T., PRYOR, W. A., AMES, B. N., SAUL, R. L., McCORD, J. M., & HARMAN, D. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-4-526 · Cited by 1,856
Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects
Nehlig, A., Daval, J., & Debry, G. (1992) · Brain Research Reviews · doi:10.1016/0165-0173(92)90012-b · Cited by 1,463

Show all 240 references

Research works printed but not linked: 13

Breteler, 1995, Risk factors for Parkinson's disease: A population-based case-control study, Neurology, 45, A214
Campanella, 1990, Etiology of Parkinson's disease: Results of two case-control studies, Mov Disord, 5, 31
Davanipour, 1990, Residential histories in Parkinson's disease patients, Ann Neurol, 28, 295
Goetz, 1990, Motor vehicle accident and Parkinson's disease disability, Mov Disord, 5, 16
Kurth, 1995, Lack of association of CYP2D6 and MAO-B alleles with Parkinson's disease in a Kansas cohort, Neurology, 45, A429
Mjones, 1949, Paralysis agitans: A clinical and genetic study, Acta Psychiatry and Neurology, 54, 1
Rocca, 1990, Prevalence of Parkinson's disease and other parkinsonisms: A door-to-door survey in two Sicilian communities, Neurology, 40, 422
Tanner, 1989, Dietary antioxidant vitamins and the risk of developing Parkinson's disease, Neurology, 39, 181
Tanner, 1988, Vitamin use and Parkinson's disease, Ann Neurol, 233, 182
Treves, 1990, Case-control study, with use of temporal approach, for evaluation of risk factors for Parkinson's disease, Mov Disord, 5, 11
Uitti, 1991, Parkinsonism survival in the Levodopa era, Neurology, 41, 190
Vierregge, 1991, Parkinson's disease in twins, Neurology, 41, 255
Zimmerman, 1991, Parkinson's disease in monozygotic twins: A followup, Neurology, 41, 255

Sorted by citations

Items 501–600 of 640

Quivering hand and heart: Parkinson's disease is not associated with increased in-hospital mortality in atrial fibrillation hospitalizations: A nationwide analysis
Ukenenye, E. U., Oshiba, T., Okoronkwo, E., Obomanu, E., Asaolu, G., Urhi, A., Olateju, I. V., Onyemarim, H., Uzzi, C. I., Alugba, G., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14725 · Cited by 3
Pesticide Exposure as a Risk Factor for Parkinson's Disease
Saad, F. E.-Z., Lelo, A. P., Smimih, K., El‐Mansoury, B., lkhanouchi, M., Amine, S. E., & Bitar, A. (2023) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-6684-5156-4.ch011 · Cited by 3
Detection of Parkinson's Disease Through Spiral Drawings Using Convolutional Autoencoders
Kasab, M. W., Masri, N. A., & Moghrabi, R. A. (2024) · International Conference on Smart Systems and Power Management (IC2SPM) · doi:10.1109/ic2spm62723.2024.10841337 · Cited by 3
“With a rate of roughly 0.5–1% in people 65–69 years old, increasing to 1-3 percent in people 80 years of age and above [3].”
Influential
A case of ST elevation myocardial infarction precipitated by methylphenidate therapy for gait freeze
Connell, C., Gellatly, R. M., Dooley, M. J., & Shaw, J. A. (2015) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1077 · Cited by 3
Early-Adult Life Correlates of Personality in Parkinson’s Disease
Sullivan, K. L., Mortimer, J. A., Wang, W., Zesiewicz, T. A., Brownlee, H. J., & Borenstein, A. R. (2014) · Journal of Neurology Research · doi:10.14740/jnr.v4i2-3.280 · Cited by 3
The incidence of Parkinson's disease among Vilnius inhabitants
Juozulynas, A. (2006) · Cited by 3
Design of Wireless Electromyography (EMG) Monitoring System for Muscle Activity Detection on Parkinson Disease
Fadhlannisa, N. F., & Basari, B. (2020) · International Conference on Smart Technology and Applications (ICoSTA) · doi:10.1109/icosta48221.2020.1570609982 · Cited by 3
Demography and Epidemiology of Age-Associated Neuronal Impairment
Cassel, C. K., & Ek, K. (2001) · Elsevier eBooks · doi:10.1016/b978-012351830-9/50006-8 · Cited by 3
Mitochondrial Function and Neurodegenerative Diseases
Wilkins, H. M., Weidling, I., Koppel, S., Wang, X., von Schulze, A., & Swerdlow, R. H. (2018) · The Molecular and Cellular Basis of Neurodegenerative Diseases · doi:10.1016/b978-0-12-811304-2.00013-4 · Cited by 2
The process of angiogenesis in neurodegeneration—pathomechanisms and new therapeutic interventions
Kieliszek-Ryba, P., Jakimiuk, A., Kurek, J., Simola, N., Caria, F., Piątkowska‐Chmiel, I., & Herbet, M. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06874-z · Cited by 4
AAV-mediated intracerebral expression of an α-synuclein-targeting intrabody improves motor functions in aged rats
Wu, K., Chiu, Y.-S., Yu, S., Wang, Y.-S., Chen, C.-T., Peng, Y., Chuang, Y.-M., Chu, C.-Y., Li, Y.-C., Wang, K.-L., et al. (2026) · Scientific Reports · doi:10.1038/s41598-025-34908-1 · Cited by 2
Parkinson's Disease Database in the Middle East, North Africa, and South Asia Countries
Khalil, H. W., Shraim, M., Jaradat, B., IBRAHIM, R. H. A., Kamel, W. A., Khan, S., Aldughmi, M., Amer, H. M. A., Al‐Qassabi, A., Al‐Sharman, A., et al. (2025) · International Journal of Public Health · doi:10.3389/ijph.2025.1608016 · Cited by 2
“This rises to 1% – 3% in those older than 80 [7, 8].”
Unraveling Parkinson’s disease: from dopaminergic dysfunction to novel therapeutic targets
Godde, K., Raut, S. P., Rokde, R., & Zatke, L. (2025) · Geriatric Care · doi:10.4081/gc.2025.13936 · Cited by 2
Scenes in movement. Movement disorders on film
Romero, J. O. (2010) · Neurología (English Edition) · doi:10.1016/s2173-5808(10)70021-3 · Cited by 2
PPN Stimulation for Parkinson's Disease
Stone, S. S. D., Hamani, C., & Lozano, A. M. (2009) · Springer eBooks · doi:10.1007/978-3-540-69960-6_98 · Cited by 2
Biomarkers of Parkinson’s disease
Jin, H., Kanthasamy, A., Anantharam, V., & Kanthasamy, A. G. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404630-6.00049-x · Cited by 2
Anti-parkinsonian efficacy of target-specific GSK3β inhibitors demonstrated in Caenorhabditis elegans
Pradeep, H., Shashikumar, S., Rajini, P. S., & Rajanikant, G. K. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1078-x · Cited by 2
“It affects 1 % of the population worldwide with a median age of onset of 60 (Tanner and Goldman, 1996).”
Background
Caffeine and Neuroprotection in Parkinson’s Disease
Rodrigues, F. B., Caldeira, D., Ferreira, J. J., & Costa, J. G. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-20273-0_12 · Cited by 2
Parkinson's Disease: Drug Therapy Considerations for Rehabilitation
Mattox, K. M., Port, J. L., Lin, J. D., & Bero, K. (2001) · Topics in Geriatric Rehabilitation · doi:10.1097/00013614-200112000-00006 · Cited by 2
Neuroepidemiology: Fundamental Considerations
Nelson, L. M., Tanner, C. M., Eeden, S. K. V. D., & McGuire, V. M. (2004) · doi:10.1093/acprof:oso/9780195133790.003.01 · Cited by 2
Self-citation
Prevalence and Predisposing Factors of Parkinson Disease: A Community-Based Study In Barangay Mangilag Sur, Candelaria, Quezon: A Research Protocol
Robles, D. J. S. J., Rodriguez, R. C. N. T., Romana, N. B. S., Rosales, J. M. B., Rosales, M. C. E., Salazar, G. B., & Rosales, R. L. (2017) · Journal of Medicine University of Santo Tomas · doi:10.35460/2546-1621.2017-0057 · Cited by 2
Assessment of the efficacy of electrical vestibular nerve stimulation as an adjunct therapy in the management of motor functions and quality of life in patients with Parkinson’s disease
Sai Sailesh Kumar, G., Gawarikar, S., Choudhary, A., Potey, G. G., Purohit, M. R., Pathak, A., Chouhan, R. S., & Mahadik, V. K. (2022) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v13i3.42237 · Cited by 2
Dysfunction of mitochondria as the basis of Parkinson’s disease
Popis, M. (2018) · Medical Journal of Cell Biology · doi:10.2478/acb-2018-0027 · Cited by 2
“Moreover, they allow for the control of morphology, subcellular location and function of mitochondria [81].”
Background
Complications of levodopa therapy in Parkinson’s disease
Dubow, J. S., & Olanow, C. W. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1662294 · Cited by 2
“5% to 1% among persons 65 to 69 years of age, rising to 1% to 3% among persons 80 years of age and older [1].”
Background
Mitochondrial dysfunction in diabetes mellitus
Anderson, C. M. (1999) · Drug Development Research · doi:10.1002/(sici)1098-2299(199901)46:1 · Cited by 18
Small Extracellular Vesicles Secreted by Region-specific Astrocytes Ameliorate the Mitochondrial Function in a Cellular Model of Parkinson’s DiseasePreprint
Leggio, L., L’Episcopo, F., Magrì, A., Ulloa-Navas, M. J., Paternò, G., Vivarelli, S., Bastos, C. A. P., Tirolo, C., Testa, N., Caniglia, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.23.441135 · Cited by 2
Deep learning analysis of figure copying tasks for Parkinson’s disease detection with GAN-based data augmentation
Vallejo, M., Alty, J., & Smith, S. L. (2026) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2026.111106 · Cited by 1
A Comprehensive Review of Nanoemulsion Via the Nose To the Brain in the Management of Parkinson’s Disease
Mahajan, H. S., Sarode, R. J., Deshmane, S. V., Girnar, G., & Khedekar, S. (2025) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-025-10170-w · Cited by 1
Computational analysis of transcriptome data and mapping of functional networks in Parkinson’s disease
Perperidis, K., Exarchos, T. P., Vrahatis, A. G., Vlamos, P., & Krokidis, M. G. (2025) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2025.1690229 · Cited by 1
“Genetic predisposition is also considered a significant risk factor, as familial cases of Parkinson’s disease have been reported, suggesting a possible autosomal-dominant pattern of inheritance (Tanner and Goldman, 2005).”
Evaluation of idiopathic olfactory dysfunction as a warning marker for early parkinson’s disease: a population-based cross-sectional study
Vedadi, Z., Miandehi, E. E., Akbari, M., Shoeibi, A., Vedadi, D., Eslami, S., & Taherzadeh, Z. (2026) · Scientific Reports · doi:10.1038/s41598-026-36736-3 · Cited by 1
Parkinson’s Disease: Insights from the Laboratory and Clinical Therapeutics
Zhou, J.-Y., Yu, Y., Zhu, X.-L., Ng, C.-P., Lü, G., & Poo, W.-S. (2012) · InTech eBooks · doi:10.5772/33092 · Cited by 1
Veränderungen der spinalen und supraspinalen Schmerzwahrnehmung bei Patienten mit M. Parkinson
Marburg, S. (2009) · Cited by 1
Molecular Chaperones as Potential Therapeutic Targets for Neurological Disorders
Delenclos, M., & McLean, P. J. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849739689-00392 · Cited by 1
The Rotenone Model of Parkinson's Disease in Studying the Mechanisms of Nigrostriatal Cell Death
Abdel‐Salam, O. M. E. (2015) · Cited by 1
Parkinson’s Disease in Humans and in Nonhuman Primate Aging and Neurotoxin Models
Metzger, J. M., Jones, C. A., & Emborg, M. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811353-0.00046-4 · Cited by 1
Effectiveness of Speech Analysis in Classification of Neurodegenerative Diseases: A Study on Parkinson's Disease
Appakaya, S. B., & Sankar, R. T. (2018) · IEEE SoutheastCon · doi:10.1109/secon.2018.8479016 · Cited by 1
A Case Report on a Novel PINK1 Gene Mutation in a Female with a Neurodegenerative Disorder
Bandla, S. S., Srilekha, A., Karchalkar, P., Gayatri, S., & Ananthapur, V. (2022) · EMJ Neurology · doi:10.33590/emjneurol/21-00206 · Cited by 1
Assessment of progression of Parkinson’s disease using magnetic resonance morphometry
Vlasova, I. A., Trufanov, A. G., Buriak, A. B., Kuznetsova, E. V., Odinak, M. M., & Litvinenko, I. (2022) · Russian neurological Journal · doi:10.30629/2658-7947-2022-27-4-37-43 · Cited by 1
Immunopathogenesis of Alzheimer’s disease, Parkinson’s Disease, and other Neurodegenerative Diseases
Kumar, S., Shukla, A. K., Yadav, V. K., Srivastava, A., Dwivedi, D., & Singh, S. P. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815238754124010006 · Cited by 1
Mitochondria and Parkinson’s Disease
Swerdlow, R. H. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-006-3_10 · Cited by 1
Calpain Proteolysis and the Etiology of Parkinson’s Disease: An Emerging Hypothesis
Crocker, S. J., Smith, P. D., & Park, D. S. (2006) · Springer eBooks · doi:10.1007/0-387-23101-3_2 · Cited by 1
A Review on Parkinson’s Disease: Its Pathophysiology, Treatment and Surgery
Singh, D., Shrimali, S., & Ks, R. (2015) · Pharmatutor · Cited by 1
Traitement initial de la maladie de Parkinson : étude sur l’application des règles de consensus de mars 2000 dans la région Nord Pas-de-Calais
Simonin, C., Defebvre, L., & Destée, A. (2004) · Revue Neurologique · doi:10.1016/s0035-3787(04)71161-3 · Cited by 1
High accuracy multilayer autoencoder trained classification method for diagnosis of Parkinson’s disease using vocal signals
Rawat, A., Mishra, S., Sharma, Y., & Khetarpal, P. (2022) · Journal of Information and Optimization Sciences · doi:10.1080/02522667.2022.2036355 · Cited by 1
Indicators of Early Adult and Current Personality in Parkinson's Disease
Sullivan, K. L. (2011) · Digital Commons - University of South Florida (University of South Florida) · Cited by 1
Genetics of Parkinson's disease - with focus on genes of relevance for inflammation and dopamine neruon development
Zettergren, A. (2010) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
Maximizing the Benefit: Risk Ratio of Levodopa Therapy in Parkinson's Disease
Gottwald, M. D. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.17.162s.30884 · Cited by 1
Épidémiologie
Chrysostome, V., & Tison, F. (2011) · Elsevier eBooks · doi:10.1016/b978-2-294-71153-4.00001-9 · Cited by 1
Parkinson's Disease
Goldman, S. M. (2013) · Wiley eBooks · doi:10.1002/9781118679654.ch18 · Cited by 1
Self-citation
Parkinson's Disease
Yahr, M. D., & Brodsky, M. (2002) · Elsevier eBooks · doi:10.1016/b0-12-227210-2/00269-7 · Cited by 1
Affinity of dihydropyrimidone analogues for adenosine A1 and A2A receptors
Katsidzira, R. M. (2014)
An Overview of the Major CNS Disorders
Kelly, J. P. (2009) · doi:10.1002/9780470682920.ch2
Estrés oxidativo, metabolitos oxidados de dopamina y enfermedad de Parkinson
Santiago López, D., & Rivas Arancibia, S. (2008)
Ensuring good nutritional status in patients with Parkinson's disease: challenges and solutions
Baroni, L., & Zuliani, C. (2014) · Journal of Parkinsonism and Restless Legs Syndrome · doi:10.2147/jprls.s49186
Role of Trichloroethylene in Parkinson’s Disease
Goldman, S. M., & Cash, S. W. (2014) · Molecular and integrative toxicology · doi:10.1007/978-1-4471-6311-4_6
Self-citation
Approach to the patient presenting with parkinsonism
Kompoliti, K., & Goetz, C. G. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544873.038
Clinical experience in the Hospital Central Militar with bilateral deep brain stimulation of ventro-medial globus pallidus in patients with Parkinson's disease
Rodríguez, F. M., Sánchez, R. Y., Carrasco-Vargas, H., Samano-Osuna, A., & Jiménez-Ponce, F. (2014) · Revista Médica Del Hospital General De México · doi:10.1016/j.hgmx.2014.11.001
Verb Use in Parkinson's Disease
Nikumb, S. S. (2014) · Scholarship@Western (Western University)
Strategies for Parkinson’s Disease Care: Prevention and Management of Motor Fluctuations
Elmer, L. W., & Hauser, R. A. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.55
Parkinson's Disease
Marras, C., & Tanner, C. M. (2003) · Elsevier eBooks · doi:10.1016/b978-012566652-7/50028-9
Self-citation
The Influence of the PD-associated Gene Products PINK1 and HtrA2/Omi on Mitochondrial Integrity
Holmström, K. M. (2010)
This student paper was written as an assignment in the graduate course Free Radicals in Biology and Medicine
Buettner, G. R., Oberley, L. W., Spitz, D. R., & Domann, F. E. (2003)
The design, synthesis and evaluation of aminocaffeine derivatives as inhibitors of monoamine oxidase B
Moraal, C. (2011)
Schmerzwahrnehmung und Schmerzempfindung bei Progressiver Supranukleärer Blickparese (PSP)
Dohmann, H. (2013) · open_UMR Marburg DSpace 10.0 (Philipps-Universität Marburg) · doi:10.17192/z2013.0132
Aus dem Zentrum für Neurologie der Universität Tübingen Abteilung Neurologie mit Schwerpunkt Neurodegenerative Erkrankungen
Direktor, Ä., & Gasser, T. (2006)
Dissertation zur Erlangung des Doktorgrades der Fakultät für Chemie und Pharmazie
Schlehe, J. S. (2008)
Treatment possibilities of Alzheimer's disease.
Miklya, I., & Gaszner, P. (2004) · PubMed
DOPAMINE HOMEOSTASIS AND ENVIRONMENTAL RISK FACTORS IN A PARKINSON'S DISEASE MODEL
Smith-Somerville, H., Vincent, J. B., & Churchill, P. F. (2011)
Molecular Biotechnology Programme
Nilsson, A. (2005)
Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1236 Pharmacotherapy for Parkinson's Disease - Observations and Innovations
Nyholm, D. (2003)
"Alterações do sono na Doença de Parkinson"
Martins, P. M. C. (2011) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/yycs-ta18
Folding, function and subcellular localization of parkin
Schlehe, J. S. (2008) · doi:10.5282/edoc.9266
Selenoproteins and Brain Diseases
Panee, J., Bellinger, F. P., & Berry, M. J. (2011) · Advanced topics in science and technology in China · doi:10.1007/978-3-642-22236-8_11
Suicide-Related Behaviour in Later Life: Examining Risk and Protective Factors among Older Adults Receiving Home Care Services in Ontario, Canada
Neufeld, E. (2013) · UWSpace (University of Waterloo)
An algorithm suitable for online identification of subthalamic nucleus from microelectrode recording data
Zhang, Y. (2013) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t3mw2ftj
NEUROENDOCRINOLOGIC CONSIDERATIONS IN PARKINSON DISEASE AND OTHER MOVEMENT DISORDERS
Malaty, I. A., Lansang, M. C., & Okun, M. S. (2009) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000300028.61027.6f
Rehabilitation strategies for mobility impairment in Parkinson's disease- Where are we now?
Srinivasan, A. (2011)
Clinical and genetic analysis of levodopa induced dyskinesia in patients with Parkinson's disease
Djuric, G. (2013) · doi:10.2298/bg20130626djuric
Chapter 17Neurological Disorders
Trevathan, E. (2010) · American Public Health Association eBooks · doi:10.2105/9780875531922ch17
Neurotransmission, Oxidative Stress, and Coexistence of Neurotransmitters in Parkinson's Disease
Qureshi, G. A. (2007) · Elsevier eBooks · doi:10.1016/b978-044452809-4/50159-9
Medical risk factors for falls
Lord, S. R., Sherrington, C., Menz, H. B., & Close, J. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511722233.007
A Plant-Food Diet in the Risk and Management of Parkinson’s Disease
Baroni, L., & Zuliani, C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411462-3.00043-6
Evaluation of depth perception in elder with Parkinson's disease
Ou, Y., Lin, C., Fang, C.-W., & Liu, Y. (2016) · International Conference on Applied System Innovation · doi:10.1109/icasi.2016.7539856
Quantification of postural stability in Parkinson's disease patients using mobile technology
Ozinga, S. J. (2015) · OhioLink ETD Center (Ohio Library and Information Network)
Variables contributing to listener effort in speakers with Parkinson's disease
Wilson, C. (2016) · Scholarship@Western (Western University)
19. Neurological Disorders
Trevathan, E. (2016) · American Public Health Association eBooks · doi:10.2105/9780875532783ch19
Is Online Motor Control Really Impaired In Parkinson's Disease?
Merritt, K. E. (2016) · Scholarship@Western (Western University)
Helicobacter pylori cytotoxin-associated gene A genotype in Egyptian patients with Parkinson’s disease: could eradication benefit?
Mashaly, M. E.-S., Saudy, N., Belal, T., & Motawei, S. M. (2017) · Comparative Clinical Pathology · doi:10.1007/s00580-017-2460-0
Perfil dos indivíduos com doença de Parkinson atendidos no setor de fisioterapia de um hospital universitário no Rio de Janeiro Profile of individuals with Parkinson's disease cared in a physical therapy sector of an university hospital in Rio de Janeiro
Cristina, D., da Silva, L., Vianna, É. G., Martins, C. P., Martins, J. V., Rodrigues, É. C., Alice, L. G., & de Oliveira, S. (2015)
Need for Registration and Reporting of Acupuncture Trials in Parkinson’s Disease in Korea
Lee, T. E., Kim, A., Jang, M., & Jeon, B. (2017) · Journal of Movement Disorders · doi:10.14802/jmd.17047
Parkinson : la rééducation virtuelle et la physiothérapie classique ont un effet comparable
Winteler, B., & Monnin, D. (2017) · Kinésithérapie la Revue · doi:10.1016/j.kine.2017.11.002
Cane Use in Patients with Parkinson’s Disease
Hüzmeli, E. D., & Okuyucu, E. E. (2018) · Journal of Neurology and Experimental Neuroscience · doi:10.17756/jnen.2018-033
Hallucinations in Neurological Disorders
Fonzo, A. D., Monfrini, E., Basilico, P., & Arighi, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-75124-5_7
Parkinsonism
Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50007-3
Parkinson’s Disease
Tel, B. C., & Çakmaklı, G. Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803796-6.00013-7
Automatización de pruebas clínicas para el diagnóstico y monitoreo de la enfermedad de Parkinson
Arango Paredes, J. D., Ariza Araujo, Y. J., Navarro Cadavid, A., Orozco Vélez, J. L., Muñoz Ospina, B. E., Ágredo Rodríguez, W., & Castaño Pino, Y. J. (2019) · Editorial Universidad Icesi eBooks · doi:10.18046/eui/iys.1.2019
Neurodegenerative disorders
Itabashi, H. H., Andrews, J. M., Tomiyasu, U., Erlich, S. S., & Sathyavagiswaran, L. (2007) · Elsevier eBooks · doi:10.1016/b978-012058527-4/50016-x
Neuropeptide cocaine- and amphetamine-regulated transcript usage in Parkinson's disease
Mao, P., & Mao, Y. V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815946-0.00039-9
Automatic psychomotor function quantification in Parkinson’s disease via natural interaction with digital devices
Arroyo‐Gallego, T. (2020) · doi:10.20868/upm.thesis.64517
Detecção Precoce das Doenças de Alzheimer e Parkinson através de Parâmetros Não-Lineares Multibanda de Sinais EEG
Silva, G., Alves, M., Bispo, B. C., & Rodrigues, P. (2020) · Anais de XXXV Simpósio Brasileiro de Telecomunicações e Processamento de Sinais · doi:10.14209/sbrt.2020.1570641727

Authors: Tanner, C. M., & Goldman, S. M.
Affiliations: Parkinson's Institute and Clinical Center (US)
ORCID: Tanner, Caroline M.
Goldman, Samuel M.
Venue: Neurologic Clinics
Publisher: Elsevier BV
Published: 1996-05
Volume: 14
Issue: 2
Pages: 317-335
ISSN: 0733-8619 (ISSN-L)
DOI: 10.1016/s0733-8619(05)70259-0
PMC: PMC7173037
OpenAlex: W2084553926
Semantic Scholar: 722f96a983f226977773068a6a70c00979c0cbd5
Cited by: 640
References: 240
Citations by year: 2026: 9 · 2025: 10 · 2024: 17 · 2023: 29 · 2022: 23 · 2021: 26 · 2020: 14 · 2019: 24 · 2018: 35 · 2017: 36 · 2016: 28 · 2015: 26 · 2014: 32 · 2013: 28 · 2012: 19
FWCI: 11.14
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Neurologic Clinics (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (R01CA094089)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: Parkinson's disease, etiology, complex diseases, genetic risk factors, environmental risk factors, incidence, prevalence, levodopa, early markers, disease susceptibility, disease progression
MeSH terms: Aged, Consanguinity, Diet, Environmental Exposure, Female, Humans, Male, Middle Aged, Parkinson Disease, Risk Factors, Smoking, Global Health, Hazardous Substances, Incidence, Prevalence, Age Distribution, Sex Distribution, Patient Selection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology of parkinson’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks